[ad_1]
FRANKFURT (Dow Jones) – The Gerresheimer medical technology company takes up to 350 million euros for the resumption of the Swiss injector manufacturer Sensile Medical AG. The company develops drug distribution products and platforms, including digital networks, Gerresheimer said. The total purchase price is due only at the achievement of certain milestones, the initial payment is 175 million euros.
Still, Gerresheimer won two important new contracts, one for the manufacture of inhalers and the other for prefillable syringes for a major manufacturer of heparin. On the other hand, Gerresheimer loses a much lower order in the inhalation sector with subsequent restructuring costs for the Küssnacht factory (Switzerland), which should be closed down from here. the end of 2019.
Orders are expected to increase by 2 to 4 percentage points of neutral sales in terms of currencies in 2019 and 2020, including the expansion of the capacity of the Czech factory. Adjusted EBITDA margin is expected to reduce this percentage by 1 percentage point. For the years 2021 and 2022, Geresheimer also expects, regardless of Sensile Medical, that on the one hand sales will increase by more than 2 percentage points than usual growth and adjusted EBITDA margin and The other hand the volume of investment will drop again by 8%.
For 2018, excluding Sensile Medical, Gerresheimer expects a strong second half, specifying the forecast of high-end business adjusted for currency fluctuations of 1.38 billion euros. euros to 1.4 billion euros.
Contact's author: [email protected]
DJG / jhe / sha
(END) Newspaper Wire from Dow Jones
Posted by Jean-Marc at address 12: 22 0 Comments Email this BlogThis! ] (function (d, s, id) {
var js, fjs = d.getElementsByTagName (s) [0];
if (d.getElementById (id)) returns;
js = d.createElement (s); js.id = id;
js.src = "http://connect.facebook.net/en_US/all.js#xfbml=1&status=0";
fjs.parentNode.insertBefore (js, fjs);
} (document, 'script', 'facebook-jssdk'));
[ad_2]
Source link
